An Impact Company Committed to Improving the Health of Patients Worldwide, MedinCell Publishes Its 2021-2022 ESG Annual Report
17 Agosto 2022 - 1:00PM
Business Wire
MedinCell's annual ESG report goes into detail on the different
pillars of its ESG policy, its implementation through concrete and
clearly defined objectives, and the evolution of the company's
extra-financial data.
Access MedinCell's ESG performance in a
nutshell
Download the 2021-2022 ESG annual
report
About the publication of this report, Christophe Douat, CEO of
MedinCell, declared: "What is called CSR is at the heart of our
humanist pharma company model and of the shared-value with all our
employees since MedinCell was established. It is a virtuous process
of continuous improvement at all levels of the company. This year,
we implemented an ESG committee at the highest level of governance
to guarantee the sustainability of our commitment. We have also
improved our extra-financial performance by working on several
topics such as transparency, environment, corporate governance, and
ethics. And the best is still to come, with the first treatment
based on our technology expected to be approved in 2023. Based on
excellent clinical trial results, it should have a real impact on
the lives of patients with schizophrenia, on caregivers who support
them, and on society. This is our “raison d’être”! »
About MedinCell
MedinCell is a pharmaceutical company at premarketing stage that
develops a portfolio of long-acting injectable products in various
therapeutic areas by combining its proprietary BEPO® technology
with active ingredients already known and marketed. Through the
controlled and extended release of the active pharmaceutical
ingredient, MedinCell makes medical treatments more efficient,
particularly thanks to improved compliance, i.e. compliance with
medical prescriptions, and to a significant reduction in the
quantity of medication required as part of a one-off or chronic
treatment. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months starting from the
subcutaneous or local injection of a simple deposit of a few
millimeters, fully bioresorbable. MedinCell collaborate with tier
one pharmaceuticals companies and foundations to improve Global
Health through new therapeutic options. Based in Montpellier,
MedinCell currently employs more than 150 people representing over
30 different nationalities. www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220817005533/en/
MedinCell David Heuzé Communication leader
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier/Olivier Bricaud Investor
Relations medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024